Development of the Adult Vulvar Lichen Sclerosus Severity Scale-A Delphi Consensus Exercise for Item Generation

Michal Sheinis, Amanda Selk, Michal Sheinis, Amanda Selk

Abstract

Objective: To generate a list of items through international expert consensus consisting of both symptoms and clinical signs for inclusion in an adult vulvar lichen sclerosus severity scale.

Methods: This study was carried out as a three-stage Delphi consensus exercise. After an extensive literature review, any items used to determine disease severity in previous clinical trials were compiled into a survey. The Delphi participants were recruited from the International Society for the Study of Vulvovaginal Disease most of whom were gynecologists and in practice for more than 20 years. Participants were asked to rate the importance of these items. Consensus was defined as 75% agreeing that an item was very important or essential toward determining disease severity. Participants were also asked to indicate preferred method of measurement for these items.

Results: Of approximately 400 members of the International Society for the Study of Vulvovaginal Disease, 66 participated in the study. Of the 14 symptoms presented, 7 reached consensus for inclusion. Of the 23 signs presented, 11 reached consensus for inclusion and 1 reached consensus for exclusion. Of the six architectural changes presented, all six reached consensus for inclusion. No consensus was reached regarding method of measurement for any of the symptoms and signs that reached consensus for inclusion.

Conclusion: International consensus was reached for a variety of items for use in an adult vulvar lichen sclerosus severity scale that will be further developed and tested. Ideally, this scale will be used in clinical practice and in research to allow for high-quality trials.

Conflict of interest statement

The authors have declared that they have no conflicts of interest.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5768225/bin/lgt-22-66-g006.jpg

References

    1. Tasker GL, Wojnarowska F. Lichen sclerosus. Clin Exp Dermatol 2003;28:128–33.
    1. Virgili A, Corazza M, Minghetti S, et al. Growing evidence for topical mometasone fuoroate in the treatment of vulvar lichen sclerosus. Maturitas 2015;80:113–5.
    1. Virgili A, Minghetti S, Corazza M, et al. Efficacy and tolerability of mometasone furoate in lichen sclerosus: further confirming evidence. J Low Genit Tract Dis 2015;19:e58.
    1. Borghi A, Corazza M, Minghetti S, et al. Topical tretinoin in the treatment of vulvar lichen sclerosus: an advisable option? Eur J Dermatol 2015;25:404–9.
    1. Virgili A, Borghi A, Toni G, et al. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. Br J Dermatol 2014;171:388–96.
    1. Virgili A, Borghi A, Toni G, et al. Prospective clinical and epidemiologic study of vulvar lichen sclerosus: analysis of prevalence and severity of clinical features, together with historical and demographic associations. Dermatology 2014;228:145–51.
    1. Virgili A, Borghi A, Minghetti S, et al. Mometasone furoate 0.1% ointment in the treatment of vulvar lichen sclerosus: a study of efficacy and safety on a large cohort of patients. J Eur Acad Dermatol Venereol 2014;28:943–8.
    1. Virgili A, Minghetti S, Borghi A, et al. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br J Dermatol 2013;168:1316–24.
    1. Virgili A, Lauriola MM, Mantovani L, et al. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol 2007;87:69–72.
    1. The Association for Lichen Sclerosus & Vulval Health. Available at: . Accessed March 22, 2017.
    1. SurveyMonkey Inc. San Mateo, California, USA: Available at: .
    1. Fox AR, Gordon LK, Heckenlively JR, et al. Consensus on the diagnosis and management of nonparaneoplastic autoimmune retinopathy using a modified Delphi approach. Am J Ophthalmol 2016;168:183–90.
    1. Del Pino-Montes J, Blanch J, Nogués X, et al. Expert consensus on the management of patients with postmenopausal osteoporosis in the Spanish healthcare system. Adv Ther 2016;33:658–69.
    1. Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991;124:461–4.
    1. Tamburino S, Lombardo GA, Tarico MS, et al. The role of nanofat grafting in vulvar lichen sclerosus: a preliminary report. Arch Plast Surg 2016;43:93–5.
    1. LeFevre C, Hoffstetter S, Meyer S, et al. Management of lichen sclerosus with triamcinolone ointment: effectiveness in reduction of patient symptom scores. J Low Genit Tract Dis 2011;15:205–9.
    1. Murina F, Rehman S, Di Francesco S, et al. Vulvar lichen sclerosus: a comparison of the short-term topical application of clobetasol dipropionate 0.05% versus mometasone furoate 0.1%. J Low Genit Tract Dis 2015;19:149–51.
    1. Goldstein AT, Burrows LJ, Belkin ZR, et al. Safety and efficacy of human fibroblast lysate cream for vulvar lichen sclerosus: a randomized placebo-controlled trial. Acta Derm Venereol 2015;95:847–9.
    1. Cabete J, Campos S, Lestre S. Conscious sedation with inhaled 50% nitrous oxide/oxygen premix in photodynamic therapy sessions for vulvar lichen sclerosus treatment. An Bras Dermatol 2015;90:120–2.
    1. Terras S, Gambichler T, Moritz RK, et al. UV-A1 phototherapy vs clobetasol propionate, 0.05%, in the treatment of vulvar lichen sclerosus: a randomized clinical trial. JAMA Dermatol 2014;150:621–7.
    1. Patsatsi A, Kyriakou A, Mantas A, et al. Circulating anti-BP180 NC16a and anti-BP230 autoantibodies in patients with genital lichen sclerosus do not correlate with disease activity and pruritus. Acta Derm Venereol 2014;94:711–2.
    1. Lansdorp CA, van den Hondel KE, Korfage IJ, et al. Quality of life in Dutch women with lichen sclerosus. Br J Dermatol 2013;168:787–93.
    1. Goldstein AT, Creasey A, Pfau R, et al. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol 2011;64:e99–104.
    1. Zawislak AA, McCluggage WG, Donnelly RF, et al. Response of vulval lichen sclerosus and squamous hyperplasia to photodynamic treatment using sustained topical delivery of aminolevulinic acid from a novel bioadhesive patch system. Photodermatol Photoimmunol Photomed 2009;25:111–3.
    1. Stücker M, Grape J, Bechara FG, et al. The outcome after cryosurgery and intralesional steroid injection in vulvar lichen sclerosus corresponds to preoperative histopathological findings. Dermatology 2005;210:218–22.
    1. Cooper SM, Gao XH, Powell JJ, et al. Does treatment of vulvar lichen sclerosus influence its prognosis? Arch Dermatol 2004;140:702–6.
    1. D'Antuono A, Bellavista S, Negosanti F, et al. Dermasilk briefs in vulvar lichen sclerosus: an adjuvant tool. J Low Genit Tract Dis 2011;15:287–91.
    1. Ye M, Deng X, Mao S, et al. High intensity focused ultrasound treatment for non-neoplastic epithelial disorders of the vulva: factors affecting effectiveness and recurrence. Int J Hyperthermia 2015;31:771–6.
    1. Oskay T, Sezer HK, Genç C, et al. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J Dermatol 2007;46:527–32.
    1. Bulbul Baskan E, Turan H, Tunali S, et al. Open-label trial of cyclosporine for vulvar lichen sclerosus. J Am Acad Dermatol 2007;57:276–8.
    1. Hengge UR, Krause W, Hofmann H, et al. Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. Br J Dermatol 2006;155:1021–8.
    1. Al-Sebai MAH. Evening primrose oil: a possible new treatment for vulval dystrophy. J Obstet Gynaecol 1993;13:193–5.
    1. Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008;24:19–23.
    1. Paslin D. Androgens in the topical treatment of lichen sclerosus. Int J Dermatol 1996;35:298–301.
    1. Challenor R. The management of lichen sclerosus in a genitourinary medicine setting: a 12-month retrospective case-notes review. Int J STD AIDS 2015;26:352–6.
    1. Lee A, Bradford J, Fischer G. Long-term management of adult vulvar lichen sclerosus: a prospective cohort study of 507 women. JAMA Dermatology 2015;151:1061–7.
    1. Funaro D, Lovett A, Leroux N, et al. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. J Am Acad Dermatol 2014;71:84–91.
    1. Sotiriou E, Panagiotidou D, Ioannidis D. An open trial of 5-aminolevulinic acid photodynamic therapy for vulvar lichen sclerosus. Eur J Obstet Gynecol Reprod Biol 2008;141:187–8.
    1. Gupta S, Saraswat A, Kumar B. Treatment of genital lichen sclerosus with topical calcipotriol. Int J STD AIDS 2005;16:772–4.
    1. Patsatsi A, Kyriakou A, Vavilis D, et al. A therapeutic approach for female, relapsing genital lichen sclerosus: a single-center study. J Dermatolog Treat 2013;24:336–9.
    1. Sun X, Xue M, Deng X, et al. Clinical factors analysis of curative effect of focused ultrasound treatment for non neoplastic epithelial disorders of vulva. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010;35:933–9.
    1. Li C, Bian D, Chen W, et al. Focused ultrasound therapy of vulvar dystrophies: a feasibility study. Obstet Gynecol 2004;104(5 Pt 1): 915–21.
    1. Kim GW, Park HJ, Kim HS, et al. Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement. J Dermatol 2012;39:145–50.
    1. Origoni M, Ferrari D, Rossi M, et al. Topical oxatomide: an alternative approach for the treatment of vulvar lichen sclerosus. Int J Gynaecol Obstet 1996;55:259–64.
    1. Sideri M, Origoni M, Spinaci L, et al. Topical testosterone in the treatment of vulvar lichen sclerosus. Int J Gynaecol Obstet 1994;46:53–6.
    1. Paslin D. Treatment of lichen sclerosus with topical dihydrotestosterone. Obstet Gynecol 1991;78:1046–9.
    1. Ventolini G, Swenson KM, Galloway ML. Lichen sclerosus: a 5-year follow-up after topical, subdermal, or combined therapy. J Low Genit Tract Dis 2012;16:271–4.
    1. Boero V, Brambilla M, Sipio E, et al. Vulvar lichen sclerosus: a new regenerative approach through fat grafting. Gynecol Oncol 2015;139:471–5.
    1. Bradford J, Fischer G. Long-term management of vulval lichen sclerosus in adult women. Aust N Z J Obstet Gynaecol 2010;50:148–52.
    1. Ayhan A, Guven ES, Guven S, et al. Testosterone versus clobetasol for maintenance of vulvar lichen sclerosus associated with variable degrees of squamous cell hyperplasia. Acta Obstet Gynecol Scand 2007;86:715–9.
    1. Carli P, Cattaneo A, Taddei G, et al. Topical cyclosporine in the treatment of vulvar lichen sclerosus: clinical, histologic, and immunohistochemical findings. Arch Dermatol 1992;128:1548–9.
    1. Simonart T, Lahaye M, Simonart JM. Vulvar lichen sclerosus: effect of maintenance treatment with a moisturizer on the course of the disease. Menopause 2008;15:74–7.
    1. Renaud-Vilmer C, Cavelier-Balloy B, Porcher R, et al. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol 2004;140:709–12.
    1. Olejek A, Olszak-Wąsik K, Stęplewska K, et al. Efficacy of PDT in vulvar LS treatment based on immunohistochemical analysis of CD3, CD4, CD8, CD57, Granzyme B and Fascin expression. Przeglad Menopauzalny 2013;17:155–8.
    1. Olejek A, Steplewska K, Gabriel A, et al. Efficacy of photodynamic therapy in vulvar lichen sclerosus treatment based on immunohistochemical analysis of CD34, CD44, myelin basic protein, and Ki67 antibodies. Int J Gynecol Cancer 2010;20:879–87.
    1. Kauppila S, Kotila V, Knuuti E, et al. The effect of topical pimecrolimus on inflammatory infiltrate in vulvar lichen sclerosus. Am J Obstet Gynecol 2010;202:181.e1–4.
    1. Nissi R, Kotila V, Knuuti E, et al. Altered p53 and Bcl-2 expression in keratinocytes of vulvar lichen sclerosus during pimecrolimus treatment. Br J Dermatol 2009;161:958–60.
    1. Carli P, Cattaneo A, Giannotti B. Clobetasol propionate 0.05% cream in the treatment of vulvar lichen sclerosus: effect on the immunohistological profile. Br J Dermatol 1992;127:542–3.
    1. Casabona F, Priano V, Vallerino V, et al. New surgical approach to lichen sclerosus of the vulva: the role of adipose-derived mesenchymal cells and platelet-rich plasma in tissue regeneration. Plast Reconstr Surg 2010;126:210e–11e.
    1. Wehbe-Alamah H, Kornblau BL, Haderer J, et al. Silent no more! The lived experiences of women with lichen sclerosis. J Am Acad Nurse Pract 2012;24:499–505.
    1. Hillemanns P, Untch M, Pröve F, et al. Photodynamic therapy of vulvar lichen sclerosus with 5-aminolevulinic acid. Obstet Gynecol 1999;93:71–4.
    1. Selk A. A survey of experts regarding the treatment of adult vulvar lichen sclerosus. J Low Genit Tract Dis 2015;19:244–7.
    1. Chi CC, Kirtschig G, Baldo M, et al. Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus. J Am Acad Dermatol 2012;67:305–12.
    1. Shi L, Miao F, Zhang LL, et al. Comparison of 5-aminolevulinic acid photodynamic therapy and clobetasol propionate in treatment of vulvar lichen sclerosus. Acta Derm Venereol 2016;96:684–8.
    1. Borghi A, Corazza M, Minghetti S, et al. Continuous vs. tapering application of the potent topical corticosteroid mometasone furoate in the treatment of vulvar lichen sclerosus: results of a randomized trial. Br J Dermatol 2015;173:1381–6.
    1. Corazza M, Borghi A, Minghetti S, et al. Clobetasol propionate vs. mometasone furoate in 1-year proactive maintenance therapy of vulvar lichen sclerosus: results from a comparative trial. J Eur Acad Dermatol Venereol 2016;30:956–61.
    1. Walker SL, Nicholls PG, Butlin CR, et al. Development and validation of a severity scale for leprosy type 1 reactions. PLoS Negl Trop Dis 2008;2:e351.
    1. Varella AY, Fukuda JM, Teivelis MP, et al. Translation and validation of Hyperhidrosis Disease Severity Scale. Rev Assoc Med Bras (1992) 2016;62:843–7.
    1. Faria JR, Aarão AR, Jimenez LM, et al. Inter-rater concordance study of the PASI (Psoriasis Area and Severity Index). An Bras Dermatol 2010;85:625–9.
    1. Bethke G, Reichart PA. [Assessment of severity of oral lichen planus using a new clinical index]. Mund Kiefer Gesichtschir 2005;9:152–60.
    1. Foster DC, Stockdale CK, Simpson R, et al. Core outcome sets for clinical trials and observational studies in vulvovaginal disease. J Low Genit Tract Dis 2017;21:163–5.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera